secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-08-24T23:59:59+00:00
Accession:  0001847903-23-000158
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa's oral OX2R agonist ORX750 preclinically reduces cataplexy and promotes wakefulness in narcolepsy mouse model
--------------------------------------------------------------------------------

- ORX750 is a potent full agonist at human OX2R (EC50=0.11 nM) with >9,800-fold selectivity over OX1R.
- In orexin/ataxin-3 narcolepsy mice, ORX750 increased wakefulness and consolidated wakefulness dose-dependently.
- At 0.3 mg/kg, latency to sleep was 2.3 h (vs 0.69 h vehicle) and latency to cataplexy was 2.7 h (vs 1.3 h vehicle).
- ORX750 also increased EEG gamma power during wakefulness and reduced cataplexy occurrences in active-phase EEG/EMG assays.
- Company will present abstract at World Sleep Congress 2023 on October 25, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000158/0001847903-23-000158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000158/cnta-20230822.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer